Tagged: Cardiovascular Interventions

A Novel Designed TAVR System for Pure Aortic Regurgitation

JACC: Cardiovascular Interventions, Volume 16, Issue 21, 2023 Nov 13, Pages 2690-2691 | Liu, Lulu, MD; Qin, Chaoyi, MD; Shi, Jun, MD;…In the past decade, the role of transcatheter aortic valve replacement (TAVR) in the management of pure aortic regurgitation (AR) has been explored. , However, initial reports documented high rates of residual AR and device migration, necessitatin… Go to Source This article was first shared by INDoximity

Wire Snare Close Loop

JACC: Cardiovascular Interventions, Volume 16, Issue 21, 2023 Nov 13, Pages 2673-2674 | Bansal, Manish, MD; Stapleton, Gary E., MD; Gowda, Srinath T., MD;…A 22-month-old girl was referred for transcatheter patent ductus arteriosus (PDA) occlusion. Baseline hemodynamics showed a pulmonary blood flow to systemic blood flow ratio (Qp:Qs ratio) of 2.5:1. On angiography, the PDA measured ∼10 mm and 2.7 m… Go to Source This article was first shared by INDoximity

1-Year Comparison of PASCAL vs MitraClip for Mitral Valve Transcatheter Edge-to-Edge Repair

JACC: Cardiovascular Interventions, Volume 16, Issue 21, 2023 Nov 13, Pages 2687-2689 | Haschemi, Jafer, MD; Haurand, Jean Marc, MD; Oehler, Daniel, MD;…Transcatheter edge-to-edge repair of the mitral valve (M-TEER) has become a widely accepted therapy for patients with clinically relevant mitral regurgitation (MR) and heightened risk for surgical interventions. We previously reported prospective … Go to Source This article was first shared by INDoximity

Pulmonary Embolism Unplugged

JACC: Cardiovascular Interventions, Volume 16, Issue 21, 2023 Nov 13, Pages 2652-2654 | Tefera, Leben, MD; Ziada, Khaled M., MD; Cameron, Scott J., MD, PhDCorresponding Author Despite medical advances in the care of patients with thrombosis, pulmonary embolism (PE) remains a significant cause of cardiovascular death. Unless contraindicated, anticoagulation carries a Class I recommendation in the ini… Go to Source This article was first shared by INDoximity

1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI

JACC: Cardiovascular Interventions, Volume 16, Issue 20, 2023 Oct 23, Pages 2498-2510 | Valgimigli, Marco, MD, PhD; Spirito, Alessandro, MD; Sartori, Samantha, PhD;…AbstractBackgroundThe optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients on long-term oral anticoagulation (OAC) therapy is still uncertain. ObjectivesThe aim of this analysis was to ass… Go to Source This article was first shared by INDoximity